Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2020
The coronavirus pandemic is reigniting a fierce debate over compounded drugs
9 June 2020 - In hopes of alleviating potential drug shortages and other issues wrought by the coronavirus pandemic, the ...
Posted by Michael Wonder on 28 May 2020
Tax payers paid to develop remdesivir but will have no say when Gilead sets the price
27 May 2020 - Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus ...
Posted by Michael Wonder on 21 May 2020
Coronavirus revives debate over drug pricing
21 May 2020 - Lure of profits laid groundwork for some COVID-19 treatments, though may not determine who finds a cure. ...
Posted by Michael Wonder on 18 May 2020
Beware of underpriced drugs for COVID-19 treatments
18 May 2020 - It has become painfully obvious that the only path back to normalcy involves either an effective ...
Posted by Michael Wonder on 17 May 2020
Less than a movie ticket or ‘impossible to overpay’? Experts name their price for remdesivir
15 May 2020 - Two weeks ago, the world learned that remdesivir, a treatment from Gilead Sciences, has a moderate ...
Posted by Michael Wonder on 07 May 2020
Generic drug maker admits to fixing prices for cholesterol medication
7 May 2020 - For conspiring to inflate drug prices, Apotex will pay $24 million and cooperate with the Justice Department’s ...
Posted by Michael Wonder on 06 May 2020
Jaguar Health says recent drug price hikes not tied to COVID-19 pandemic
6 May 2020 - Jaguar Health Inc’s recent price hikes on its anti-diarrhoeal drug, Mytesi, were not tied to the ...
Posted by Michael Wonder on 06 May 2020
Will Gilead price its coronavirus drug for public good or company profit?
7 May 2020 - Gilead faces a new dilemma in deciding how much it should profit from the only treatment so ...
Posted by Michael Wonder on 06 May 2020
Remdesivir helps coronavirus patients — but at what cost?
6 May 2020 - Drug maker Gilead is known for creating breakthrough drugs and selling them at a premium. ...
Posted by Michael Wonder on 05 May 2020
Teva and Celltrion Healthcare announce the launch of Truxima (rituximab-abbs) injection for rheumatoid arthritis, the only biosimilar to Rituxan (rituximab) available in the United States for this indication
4 May 2020 - Truxima is also now available for the treatment of granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. ...
Posted by Michael Wonder on 05 May 2020
Gilead's drug pricing in the crosshairs again in wake of OK to use remdesivir against COVID-19
4 May 2020 - Gilead plans to spend $1 billion on its COVID-19 drug remdesivir. Now some members of Congress ...
Posted by Michael Wonder on 04 May 2020
U.S. law makers question Jaguar Health on price hike of drug that may help treat COVID-19 patients
4 May 2020 - The chair of a House of Representatives committee and a fellow Democratic committee member on Monday ...
Posted by Michael Wonder on 25 Apr 2020
Maker of drug touted as coronavirus cure accuses China of gouging
24 April 2020 - Hydroxychloroquine controversially pushed by Trump as COVID-19 remedy. ...
Posted by Michael Wonder on 23 Apr 2020
Drug maker tripled the price of a pill as it pursued coronavirus use
23 April 2020 - This month, Jaguar Health more than tripled the price of its lone FDA approved drug, right after ...
Posted by Michael Wonder on 15 Apr 2020
Merck announces US launch of Ontruzant (trastuzumab-dttb), a biosimilar of Herceptin (trastuzumab)
15 April 2020 - Merck today announced the U.S. launch of Ontruzant (trastuzumab-dttb), as a biosimilar of the reference biologic ...